Caris Life Sciences has launched Caris Detect, a new AI-powered blood test designed to identify cancer at earlier and more treatable stages. The test combines ultra-deep whole genome sequencing, whole transcriptome sequencing and artificial intelligence to analyze a broad range of molecular signals associated with cancer. Rather than relying on a limited set of genetic markers, the platform evaluates DNA, RNA and other biological patterns, using AI models trained to detect subtle signatures of early-stage disease across multiple cancer types.
The launch is supported by findings from the Caris Detect ACHIEVE 1 study, which evaluated the test’s performance across different cancers and stages of disease. The study demonstrated increasing sensitivity as cancers progressed, while also showing encouraging detection rates for stage I and II cancers, where early diagnosis can have the greatest impact on treatment outcomes. Performance varied across tumor types, with particularly strong results in some cancers and more modest sensitivity in others, highlighting both the promise and current limitations of multi-cancer early detection technologies.
Caris positions the test as part of a broader strategy to advance precision oncology through AI-driven diagnostics. The company already offers genomic profiling and blood-based testing platforms used to guide targeted cancer therapies, and Caris Detect expands its portfolio into the growing market for early cancer detection. As competition intensifies in multi-cancer blood testing, the company believes integrating comprehensive molecular profiling with AI can improve detection beyond approaches that rely on narrower genomic analyses. The launch also builds on Caris’ continued growth following its public listing and ongoing investment in precision medicine technologies.
Click here to read the original news story.
